directly
or indirectly dealing with any product, which has, as an ingredient,
Palbociclib or any pharmaceutically acceptable salt thereof, as would
infringe the plaintiffs ... their websites, any indication that they are marketing or offering for sale
Palbociclib or any pharmaceutically acceptable salt thereof, forthwith.
(iii) Defendant
said patents as per the Plaintiff cover two products i.e.,
Palbociclib and Crizotinib in their different forms. The Plaintiffs are
assignees to the said ... Plaintiffs is that the patents are valid till 10th January, 2023 (Palbociclib)
and 15th August, 2025 (Crizotinib) and are being infringed by the
Defendant
Page 1 of 7
Signing Date:28.10.2021
15:49:58
the infringing Palbociclib products on any of its websites without any
due authorisation or permission ... intermediary, he cannot be expected to
monitor the offering for sale of Palbociclib, on its websites, in futuro
and that, were his client
COMM)
442/2021.
2. The suit alleges that Defendant 1 was selling Palbociclib
formulations in respect of which the plaintiffs hold valid and
subsisting Indian ... directly or indirectly dealing with any
product, which has, as an ingredient, Palbociclib or any
pharmaceutically acceptable salt thereof, as would infringe
the plaintiffs
compound claimed in
the suit patent is 'Palbociclib'. The case of the Plaintiffs is that the Plaintiff
CS(COMM) 190/2022 Page ... India. The
product of the Plaintiff 'Palbociclib' is sold by the Plaintiff under the trade
names 'Ibrance' and 'Palbace
asserted in the present plaint. IN 218291
covers claims the compound Palbociclib, whereas IN 249316, IN
243571 and IN 250050 claim the compound Crizotinib. These ... manufacturers to enter into contract with the plaintiff for
manufacturing and marketing Palbociclib and Crizotinib, in which the
plaintiff holds valid patents, without obtaining
Defendants have put up new listings of
the pharmaceutical preparation PALBOCICLIB. The Defendants were
restrained in the following terms vide the said order ... Verified
Digitally Signed By:Devanshu
Signing Date:10.07.2022
18:09:11
ingredient, Palbociclib or any pharmaceutically
acceptable salt thereof, as would infringe the
plaintiffs
Pyrimidin-7-ones" which covers the pharmaceutical product
'Palbociclib'. An ad-interim injunction was granted on 29th March, 2022 in
the following ... accordingly,
restrained from manufacturing. marketing, sellins.
exporting. importins products containing 'Palbociclib'
or in any other manner infringing 'IN 218291' till
which covers and claims the
Plaintiff's commercial product 'Palbociclib', rendition of accounts,
damages, delivery up, etc. On 5th October ... rights and
contentions.
i. The Defendant will not be launching any Palbociclib
product till expiry of IN 218291on 10.01.2023 or until
there is any finding
bearing nos. IN 218291, IN
209251 & IN 232353. These patents concern Palbociclib [i.e. IN 218291];
Sunitinib [i.e. IN 209251]; and Axitinib ... Pravin Anand, who appears for the plaintiffs, says that the patent
qua Palbociclib [i.e. IN 218291] expires on 10.01.2023, whereas, the patent
concerning Sunitinib
